Perth-based clinical trials company Zelda Therapeutics
(ASX:ZLD) now has approval for their autism project involving cannabis to be conducted at the USA-based Children’s Hospital of Philadelphia.
The Institutional Review Board Approval is the equivalent to Human Research Ethics Approval here in Australia.
It essentially allows the planned study to commence within the parameters of the approved trial protocols.
The study will monitor paediatric patients already being treated with medicinal cannabis formulations.
It will identify the appropriate dosage and effectiveness.
Shares in Zelda Therapeutics
(ASX:ZLD) closed flat at $0.10
